Taysha Gene Therapies Q2 2024 GAAP EPS $(0.09) Beats $(0.10) Estimate, Sales $1.112M Miss $2.664M Estimate
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies (NASDAQ:TSHA) reported Q2 2024 GAAP EPS of $(0.09), beating the $(0.10) estimate, but missed sales estimates with $1.112M against the expected $2.664M.
August 12, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Taysha Gene Therapies reported a better-than-expected EPS of $(0.09) for Q2 2024, but significantly missed sales estimates with $1.112M compared to the expected $2.664M.
While Taysha Gene Therapies beat EPS estimates, the significant miss on sales figures and the large year-over-year decline in revenue are likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100